SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cleveland BioLabs, Inc. (Nasdaq – CBLI)

BALA CYNWYD – October 19, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cleveland BioLabs, Inc. (“Cleveland BioLabs” or the “Company”) (Nasdaq – CBLI) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to merge with Cytocom, Inc. (“Cytocom”). Under the terms of the agreement, Cleveland BioLabs stockholders will control only 39% of the combined company.

The investigation concerns whether the Cleveland BioLabs Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

If you own shares of Cleveland BioLabs stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.